Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 9, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing details the following transactions executed on January 8, 2007, and notified on January 9, 2007:
- Abacus Corporate Trustees Limited, acting as trustee for the GlaxoSmithKline (US) Trust, sold 585 Ordinary Share ADRs on behalf of participants in the GlaxoSmithKline Share Value Plan at a price of $52.88 per ADR.
- The GSK US Trust transferred 1,169 Ordinary Share ADRs to participants in the GlaxoSmithKline Share Value Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that two directors, Dr. J-P Garnier and Dr. M M Slaoui, are interested in shares held in the GSK US Trust in the same capacity as other employees or former employees of SmithKline Beecham Corporation and its subsidiaries.
Investor Verification Points
- Verify the total volume of ADRs sold (585) and transferred (1,169) within the GSK US Trust.
- Confirm the transaction price of $52.88 per ADR for the sale executed on January 8, 2007.
- Review the relationship between the GSK US Trust and the directors Dr. J-P Garnier and Dr. M M Slaoui as described in the disclosure.